Skip to the main content

Acta Pharmaceutica, Vol. 69 No. 4, 2019.

Short communication, Note

https://doi.org/10.2478/acph-2019-0053

Efficacy and safety of local lysozyme treatment in patients with oral mucositis after chemotherapy and radiotherapy

DZENANA EMINAGIĆ ; Clinical Center University of Sarajevo, Bosnia and Herzegovina
AIDA LOKVANČIĆ ; Bosnalijek JSC, Sarajevo, Bosnia and Herzegovina
BERISA HASANBEGOVIĆ ; Clinical Center University of Sarajevo, Bosnia and Herzegovina
ALMA MEKIĆ-ABAZOVIĆ ; Zenica Cantonal Hospital, Bosnia and Herzegovina
ASMIR AVDIČEVIĆ ; University Clinical Center Tuzla, Bosnia and Herzegovina
INGA MARIJANOVIĆ ; University Hospital Mostar, Bosnia and Herzegovina
SLOBODAN M. JANKOVIĆ orcid id orcid.org/0000-0002-1519-8828 ; University of Kragujevac, Faculty of Medical Sciences, Serbia
BELMA KAPO ; Bosnalijek JSC, Sarajevo, Bosnia and Herzegovina

Full text: english pdf 244 Kb

page 695-704

downloads: 1.152

cite

Abstract

This observational clinical study was composed of two substudies: a non-comparative one (n = 166), testing only lysozyme-based compounds (LBCs), and a comparative substudy (n = 275), testing both LBCs and bicarbonate-based local compounds (BBCs) on the healing of oral mucositis during radio- or chemotherapy. The density of ulcerations has decreased significantly after the treatment with lysozyme in both substudies. The density of ulcerations in the radiotherapy group was lower in patients treated with LBCs compared to patients treated with BBCs (p < 0.001). In the chemotherapy group, reduction of ulceration density was similar with both LBCs and BBCs. The LBCs reduced pain intensity during the intake of solid food and speech more than BBCs in both patient cohorts (p < 0.05). In the radiotherapy cohort, pain intensity when consuming liquid foods was reduced more with LBCs than with BBCs (p < 0.05). No adverse events were recorded. This study demonstrates the advantages of treating oral mucositis during radiotherapy or chemotherapy with LBCs.

Keywords

oral mucositis; treatment efficacy; radiotherapy; chemotherapy; topical; lysozyme

Hrčak ID:

225508

URI

https://hrcak.srce.hr/225508

Publication date:

31.12.2019.

Visits: 2.106 *